1. Home
  2. MODD vs TVRD Comparison

MODD vs TVRD Comparison

Compare MODD & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

HOLD

Current Price

$4.59

Market Cap

28.5M

Sector

Health Care

ML Signal

HOLD

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

25.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MODD
TVRD
Founded
1998
2017
Country
United States
United States
Employees
N/A
12
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5M
25.0M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MODD
TVRD
Price
$4.59
$2.27
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
39.1K
54.3K
Earning Date
02-17-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
34.62
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$2.34
52 Week High
$6.16
$43.65

Technical Indicators

Market Signals
Indicator
MODD
TVRD
Relative Strength Index (RSI) 50.83 26.19
Support Level $4.31 N/A
Resistance Level $5.80 $4.20
Average True Range (ATR) 0.78 0.22
MACD -0.09 -0.03
Stochastic Oscillator 33.78 16.92

Price Performance

Historical Comparison
MODD
TVRD

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: